Molecular Partners Ag (MOLN) Operating Expenses (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Operating Expenses of -$17166.8 for Q1 2026, up 4.38% year-over-year from -$16445.7 in Q1 2025, and up 99.97% quarter-over-quarter from -$50.2 million in Q4 2025.
Molecular Partners Ag (MOLN) Operating Expenses (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Operating Expenses for 7 consecutive years, with -$17166.8 the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 4.38% year-over-year to -$17166.8; the TTM figure through Mar 2026 stood at -$50.3 million (down 190.65% YoY), while the FY2025 annual figure was -$50.3 million, down 190.66% from the prior year.
- Operating Expenses improved to -$17166.8 in Q1 2026 per MOLN's latest filing, from -$50.2 million in the prior quarter.
- Across five years, Operating Expenses topped out at $76.9 million in Q4 2023 and bottomed at -$50.2 million in Q4 2025.
- Historically, Operating Expenses has averaged $7.1 million across 5 years, with a median of -$17953.9 in 2025.
- Annual changes were most pronounced in 2024 — Operating Expenses surged 99.89% — and 2025, when it tumbled 190.46%.
- Molecular Partners Ag's Operating Expenses stood at $75.8 million in 2022, then climbed by 1.4% to $76.9 million in 2023, then fell by 27.76% to $55.5 million in 2024, then sank by 190.46% to -$50.2 million in 2025, then jumped by 99.97% to -$17166.8 in 2026.
- Business Quant data shows MOLN's Operating Expenses at -$17166.8 in Q1 2026, -$50.2 million in Q4 2025, and -$15057.6 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 541.02 Mn |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | -17,166.77 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17,166.77 |
| Dec 31, 2025 | -50.24 Mn |
| Sep 30, 2025 | -15,057.57 |
| Jun 30, 2025 | -20,917.04 |
| Mar 31, 2025 | -17,953.95 |
| Dec 31, 2024 | 55.54 Mn |
| Sep 30, 2024 | -17,624.74 |
| Jun 30, 2024 | -19,381.24 |
| Mar 31, 2024 | -21,305.11 |
| Dec 31, 2023 | 76.88 Mn |
| Sep 30, 2023 | -18,148.41 |
| Jun 30, 2023 | -18.13 Mn |
| Mar 31, 2023 | -19,610.13 |
| Dec 31, 2022 | 75.82 Mn |
| Sep 30, 2022 | -17,660.75 |
| Jun 30, 2022 | -18.74 Mn |
| Mar 31, 2022 | 21,904.13 |
| Dec 31, 2021 | 79.42 Mn |
| Sep 30, 2021 | -17,829.04 |
| Jun 30, 2021 | -43.02 Mn |